Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Stem cell transplantation in follicular lymphoma: progress at last?

Bone Marrow Transplantation volume 34, pages 929–938 (2004)Cite this article

Summary:

Follicular non-Hodgkin's lymphomas usually present in advanced stage and although frequently are chemotherapy-sensitive remain incurable using conventional approaches. Treatment options are evolving rapidly and now include targeted therapies such as monoclonal antibodies. Recent studies, including the EBMTR-sponsored ‘CUP Trial’ (conventional Chemotherapy, Unpurged autograft, Purged autograft), demonstrate that for patients under age 60 years with recurrent chemotherapy-sensitive disease, autologous stem cell transplantation (ASCT) provides a survival benefit over conventional therapy. Allogeneic stem cell transplantation (alloSCT) has become a more effective option. Although incorporation of TBI into the preparative regimen may increase treatment-related mortality (TRM), relapses appear to be reduced compared to a chemotherapy-alone regimen. Reduced-intensity alloSCT procedures are now being performed at an increasing rate, in part due to a lower risk for TRM. Until more data are available, however, reduced-intensity alloSCT should be considered only in cases where myeloablative conditioning is contra-indicated. There are no clear means for choosing ASCT vs alloSCT, a decision influenced by the amount of residual tumor, disease-responsiveness, degree of marrow involvement and extent of prior chemotherapy. ASCT or alloSCT in first remission remains an investigational procedure. Future considerations include incorporation of novel preparative regimens, in vitro purging techniques, antilymphoma vaccines, post transplant immunotherapy and ex vivo-manipulated donor lymphocyte infusions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918.

  2. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994.

  3. Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265.

    Article  CAS  PubMed  Google Scholar 

  4. Dana BW, Dahlberg S, Nathwani BN et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 1993; 11: 644–651.

    Article  CAS  PubMed  Google Scholar 

  5. Johnson PW, Rohatiner AZ, Whelan JS et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140–147.

    Article  CAS  PubMed  Google Scholar 

  6. Bruno SCC, Santarelli MT . Randomized trial of cyclophosphamide (C) versus cyclophosphamide, vincristine, and prednisone(CVP) in low grade lymphoma (LG-NHL). Proc Am Soc Clin Oncol 1988; 7: 243 (Abstr.).

    Google Scholar 

  7. Solal-Celigny P, Lepage E, Brousse N et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med 1993; 329: 1608–1614.

    Article  CAS  PubMed  Google Scholar 

  8. Fisher RI, Oken MM . Clinical practice guidelines: non-Hodgkin's lymphomas. Cleve Clin J Med 1995; 62 (Suppl. 1): SI6–S42; quiz SI43–SI45.

    PubMed  Google Scholar 

  9. Fisher RI, Dana BW, LeBlanc M et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 2000; 18: 2010–2016.

    Article  CAS  PubMed  Google Scholar 

  10. Freedman A, Friedberg JW, Gribben J . High-dose therapy for follicular lymphoma. Oncology (Huntingt) 2000; 14: 321–326, 329; discussion 330–322, 338.

    Article  CAS  Google Scholar 

  11. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333.

    CAS  PubMed  Google Scholar 

  12. Colombat P, Donadio D, Fouillard L et al. Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant 1994; 13: 157–162.

    CAS  PubMed  Google Scholar 

  13. Bierman PJ, Vose JM, Anderson JR et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445–450.

    Article  CAS  PubMed  Google Scholar 

  14. Apostolidis J, Gupta RK, Grenzelias D et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000; 18: 527–536.

    Article  CAS  PubMed  Google Scholar 

  15. Voso MT, Martin S, Hohaus S et al. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant 2000; 25: 957–964.

    Article  CAS  PubMed  Google Scholar 

  16. Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257–3262.

    CAS  PubMed  Google Scholar 

  17. Weaver CH, Schwartzberg L, Rhinehart S et al. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21: 383–389.

    Article  CAS  PubMed  Google Scholar 

  18. Berglund A, Enblad G, Carlson K et al. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. Eur J Haematol 2000; 65: 17–22.

    Article  CAS  PubMed  Google Scholar 

  19. Brice P, Simon D, Bouabdallah R et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 2000; 11: 1585–1590.

    Article  CAS  PubMed  Google Scholar 

  20. Verdonck LF, Dekker AW, Lokhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201–4205.

    CAS  PubMed  Google Scholar 

  21. Cervantes F, Shu XO, McGlave PB et al. Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1995; 16: 387–392.

    CAS  PubMed  Google Scholar 

  22. Cao TM, Horning S, Negrin RS et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001; 7: 294–301.

    Article  CAS  PubMed  Google Scholar 

  23. van Besien K, Loberiza Jr FR, Bajorunaite R et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521–3529.

    Article  CAS  PubMed  Google Scholar 

  24. Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927.

    Article  CAS  PubMed  Google Scholar 

  25. Molina A, Nademannee A, O'Donnell MR et al. Long-term follow-up and analysis of prognostic factors after high-dose therapy (HDT) and peripheral blood stem cell autografting (ASCT) in 58 patients (pts) with a history of low grade follicular lymphoma (FLGL). Blood 1999; 94 (suppl. 1): 171a (Abstr.).

    Google Scholar 

  26. Seyfarth B, Kuse R, Sonnen R et al. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant? Ann Hematol 2001; 80: 398–405.

    Article  CAS  PubMed  Google Scholar 

  27. Stein RS, Greer JP, Goodman S et al. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant 1999; 23: 227–233.

    Article  CAS  PubMed  Google Scholar 

  28. Apostolidis J, Foran JM, Johnson PW et al. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1999; 17: 216–221.

    Article  CAS  PubMed  Google Scholar 

  29. Freedman AS, Gribben JG, Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780–2786.

    CAS  PubMed  Google Scholar 

  30. Horning SJ, Negrin RS, Hoppe RT et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97: 404–409.

    Article  CAS  PubMed  Google Scholar 

  31. Corradini P, Ladetto M, Zallio F et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22: 1460–1468.

    Article  PubMed  Google Scholar 

  32. Lenz G, Dreyling M, Schiegnitz E et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma – results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2004; in press.

  33. Colombat P, Foussard C, Bertrand P et al. Value of autologous stem cell transplantation in first line therapy of follicular lymphoma with high tumor burden: first results of the randomized GOELAMS 064 trial. Blood 2001; 98: 861a (Abstr.).

    Google Scholar 

  34. Bociek GR, Bierman PJ, Vose JM et al. High-dose therapy with autologous hematopoietic stem cell transplantation for patients (pts) with low-grade follicular non-Hodgkin's lymphoma in first complete remission (CR) or partial remission (PR). Blood 1999; 94 (Suppl. 1): 171a (Abstr.).

    Google Scholar 

  35. González-Barca E, Fernández de Sevilla A, Domingo-Claros A et al. Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission; toxicity, follow-up of minimal residual disease and survival. Bone Marrow Transplant 2000; 26: 1051–1056.

    Article  PubMed  Google Scholar 

  36. Linassier C, Fouillard L, Milpied N et al. Value of autologous bone marrow transplantation (ABMT) in 42 patients with follicular lymphomas responsive to conventional chemotherapy: a ‘France Autogreffe’ study. Cancer Detect Prev 1996; 20: 11–19.

    CAS  PubMed  Google Scholar 

  37. Lenz G, Unterhalt M, Haferlach T et al. Significant increase of secondary myelodysplasia and acute myeloid leukemia after myeloablative radiochemotherapy followed by autologous stem cell transplantation in indolent lymphoma patients – results of a prospective randomized study for the GLSG. Blood 2003; 102 (Suppl. 1): 986a–987a (Abstr. 3671).

    Google Scholar 

  38. Schouten HC, Bierman PJ, Vaughan WP et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989; 74: 2579–2584.

    CAS  PubMed  Google Scholar 

  39. Foran JM, Apostolidis J, Papamichael D et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single center. Ann Oncol 1998; 9: 865–869.

    Article  CAS  PubMed  Google Scholar 

  40. Friedberg JW, Neuberg D, Gribben JG et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 1999; 5: 262–268.

    Article  CAS  PubMed  Google Scholar 

  41. Williams CD, Harrison CN, Lister TA et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001; 19: 727–735.

    Article  CAS  PubMed  Google Scholar 

  42. Chen CI, Crump M, Tsang R et al. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haemtaol 2001; 113: 202–208.

    Article  CAS  Google Scholar 

  43. Bolwell B, Kalaycio M, Andresen S et al. Autologous peripheral blood progenitor cell transplantation for transformed diffuse large-cell lymphoma. Clin Lymphoma 2000; 1: 226–231; discussion 232–223.

    Article  CAS  PubMed  Google Scholar 

  44. Pagel JM, Matthews DC, Appelbaum FR et al. The use of radioimmunoconjugates in stem cell transplantation. Bone Marrow Transplant 2002; 29: 807–816.

    Article  CAS  PubMed  Google Scholar 

  45. Gopal AK, Gooley TA, Maloney DG et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003; 102: 2351–2357.

    Article  CAS  PubMed  Google Scholar 

  46. Knop S, Jakob A, Kanz L et al. 186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2004; 103: 1175.

    Article  CAS  PubMed  Google Scholar 

  47. Hunault-Berger M, Ifrah N, Solal-Celigny P . Intensive therapies in follicular non-Hodgkin lymphomas. Blood 2002; 100: 1141–1152.

    CAS  PubMed  Google Scholar 

  48. Finke J . The role of stem cell transplantation in the treatment of follicular lymphoma. Semin Cancer Biol 2003; 13: 233–239.

    Article  PubMed  Google Scholar 

  49. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525–1533.

    Article  CAS  PubMed  Google Scholar 

  50. Fouillard L, Laporte JP, Labopin M et al. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation – results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol 1998; 16: 2803–2816.

    Article  CAS  PubMed  Google Scholar 

  51. Martin-Henao GA, Picon M, Limon A et al. Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL). Bone Marrow Transplant 1999; 23: 579–587.

    Article  CAS  PubMed  Google Scholar 

  52. Ladetto M, Corradini P, Vallet S et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 2002; 100: 1559–1565.

    Article  CAS  PubMed  Google Scholar 

  53. Gribben JG, Neuberg D, Barber M et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83: 3800–3807.

    CAS  PubMed  Google Scholar 

  54. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–86.

    Article  CAS  PubMed  Google Scholar 

  55. Deisseroth AB, Zu Z, Claxton D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068–3076.

    CAS  PubMed  Google Scholar 

  56. McQuaker IG, Haynes AP, Anderson S et al. Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study. J Clin Oncol 1997; 15: 2288–2295.

    Article  CAS  PubMed  Google Scholar 

  57. Yerly-Motta V, Racadot E, Fest T et al. Comparative preclinical study of three bone marrow purging methods using PCR evaluation of residual t(14;18) lymphoma cells. Leuk Lymphoma 1996; 23: 313–321.

    Article  CAS  PubMed  Google Scholar 

  58. Williams CD, Goldstone AH, Pearce RM et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454–2464.

    Article  CAS  PubMed  Google Scholar 

  59. Bierman PJ, Sweetenham JW, Loberiza Jr FR et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003; 21: 3744–3753.

    Article  PubMed  Google Scholar 

  60. Flinn IW, O'Donnell PV, Goodrich A et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628–632.

    Article  CAS  PubMed  Google Scholar 

  61. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869.

    CAS  PubMed  Google Scholar 

  62. Lemieux B, Tartas S, Traulle C et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 921–923.

    Article  CAS  PubMed  Google Scholar 

  63. Gordon PR, Leimig T, Babarin-Dorner A et al. Large-scale isolation of CD133+ progenitor cells from G-CSF mobilized peripheral blood stem cells. Bone Marrow Transplant 2003; 31: 17–22.

    Article  CAS  PubMed  Google Scholar 

  64. Craiu A, Saito Y, Eppich HM et al. Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function. Blood 2004 (in press).

  65. Armitage JO . Myelodysplasia and acute leukemia after autologous bone marrow transplantation. J Clin Oncol 2000; 18: 945–946.

    Article  CAS  PubMed  Google Scholar 

  66. Armitage JO, Carbone PP, Connors JM et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21: 897–906.

    Article  PubMed  Google Scholar 

  67. Micallef IN, Lillington DM, Apostolidis J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947–955.

    Article  CAS  PubMed  Google Scholar 

  68. Krishnan AS, Bhatia SML, Slovak ML et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588–1593.

    CAS  PubMed  Google Scholar 

  69. Metayer C, Curtis RE, Vose J et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case–control study. Blood 2003; 101: 2015–2023.

    Article  CAS  PubMed  Google Scholar 

  70. Abruzzese E, Radford JE, Miller JS et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood 1999; 94: 1814–1819.

    CAS  PubMed  Google Scholar 

  71. Lillington DM, Micallef IN, Carpenter E et al. Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 2472–2481.

    Article  CAS  PubMed  Google Scholar 

  72. Baker KS, DeFor TE, Burns LJ et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352–1358.

    Article  PubMed  Google Scholar 

  73. Friedberg JW, Neuberg D, Stone RM et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128–3135.

    Article  CAS  PubMed  Google Scholar 

  74. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–1073.

    Article  CAS  PubMed  Google Scholar 

  75. Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–1533.

    Article  CAS  PubMed  Google Scholar 

  76. Sullivan KM, Storb R, Buckner CD et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989; 320: 828–834.

    Article  CAS  PubMed  Google Scholar 

  77. van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832–1836.

    CAS  PubMed  Google Scholar 

  78. Peniket AJ, Ruiz de Elvira MC, Taghipour G et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667–678.

    Article  CAS  PubMed  Google Scholar 

  79. Mandigers CM, Raemaekers JM, Schattenberg AV et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. Br J Haematol 1998; 100: 198–206.

    Article  CAS  PubMed  Google Scholar 

  80. Verdonck LF . Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience. Leuk Lymphoma 1999; 34: 129–136.

    Article  CAS  PubMed  Google Scholar 

  81. Toze CL, Shepherd JD, Connors JM et al. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 605–612.

    Article  CAS  PubMed  Google Scholar 

  82. Forrest DL, Thompson K, Nevill TJ et al. Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma. Bone Marrow Transplant 2002; 29: 973–978.

    Article  CAS  PubMed  Google Scholar 

  83. Khouri IF, Champlin RE . Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol 2004; 31: 22–26.

    Article  PubMed  Google Scholar 

  84. Faulkner RD, Craddock C, Byrne JL et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004; 103: 428–434.

    Article  CAS  PubMed  Google Scholar 

  85. Robinson SP, Mackinnon S, Goldstone A et al. Higher than expected transplant-related mortality and relapse following non-myeloablative stem cell transplantation for lymphoma adversely affects progression-free survival. Blood 2000; 96 (Suppl. 1): 554a (Abstr.).

    Google Scholar 

  86. Mandigers CMPW, Verdonck LF, Meijerink JPP et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003; 32: 1159–1163.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Comprehensive Cancer Center of Case Western Reserve University, Cleveland, OH, USA

    W W Tse & H M Lazarus

  2. Department of Medicine, University of Chicago, Chicago, IL, USA

    K Van Besien

Authors
  1. W W Tse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H M Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Van Besien
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H M Lazarus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tse, W., Lazarus, H. & Van Besien, K. Stem cell transplantation in follicular lymphoma: progress at last?. Bone Marrow Transplant 34, 929–938 (2004). https://doi.org/10.1038/sj.bmt.1704654

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704654

Keywords

This article is cited by

Search

Advanced search

Quick links